PL413705A1 - Nowe cykliczne peptydomimetyki, kompozycje je zawierające oraz ich zastosowanie do leczenia chorób związanych z angiogenezą - Google Patents

Nowe cykliczne peptydomimetyki, kompozycje je zawierające oraz ich zastosowanie do leczenia chorób związanych z angiogenezą

Info

Publication number
PL413705A1
PL413705A1 PL413705A PL41370515A PL413705A1 PL 413705 A1 PL413705 A1 PL 413705A1 PL 413705 A PL413705 A PL 413705A PL 41370515 A PL41370515 A PL 41370515A PL 413705 A1 PL413705 A1 PL 413705A1
Authority
PL
Poland
Prior art keywords
angiogenesis
treatment
application
diseases related
compositions
Prior art date
Application number
PL413705A
Other languages
English (en)
Other versions
PL227443B1 (pl
Inventor
Aleksandra Misicka-Kęsik
Karolina Grabowska
Anna Puszko
Anna Nieścioruk
Piotr Sosnowski
Bartłomiej Fedorczyk
Dagmara Tymecka
Beata Wileńska
Ewa Witkowska
Original Assignee
Uniwersytet Warszawski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Warszawski filed Critical Uniwersytet Warszawski
Priority to PL413705A priority Critical patent/PL227443B1/pl
Priority to EP16791667.5A priority patent/EP3341388B1/en
Priority to US15/755,792 priority patent/US10800814B2/en
Priority to PCT/IB2016/001247 priority patent/WO2017033055A1/en
Publication of PL413705A1 publication Critical patent/PL413705A1/pl
Publication of PL227443B1 publication Critical patent/PL227443B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Przedmiotem zgłoszenia są nowe cykliczne peptydomimetyki, kompozycje farmaceutyczne je zawierające oraz ich zastosowanie w leczeniu chorób związanych z angiogenezą, zwłaszcza nowotworów i przewlekłych stanów zapalnych w łuszczycy, cukrzycy, chorobach zwyrodnieniowych oczu (ARMD), nefropatii i neuropatii.
PL413705A 2015-08-27 2015-08-27 Nowe cykliczne peptydomimetyki, kompozycje je zawierające oraz ich zastosowanie do leczenia chorób związanych z angiogenezą PL227443B1 (pl)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL413705A PL227443B1 (pl) 2015-08-27 2015-08-27 Nowe cykliczne peptydomimetyki, kompozycje je zawierające oraz ich zastosowanie do leczenia chorób związanych z angiogenezą
EP16791667.5A EP3341388B1 (en) 2015-08-27 2016-08-29 Cyclic peptidomimetics, compositions containing them and their use in the treatment of diseases associated with angiogenesis
US15/755,792 US10800814B2 (en) 2015-08-27 2016-08-29 Cyclic peptidomimetics, compositions containing them and their use in the treatment of diseases associated with angiogenesis
PCT/IB2016/001247 WO2017033055A1 (en) 2015-08-27 2016-08-29 Cyclic peptidomimetics, compositions containing them and their use in the treatment of diseases associated with angiogenesis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL413705A PL227443B1 (pl) 2015-08-27 2015-08-27 Nowe cykliczne peptydomimetyki, kompozycje je zawierające oraz ich zastosowanie do leczenia chorób związanych z angiogenezą

Publications (2)

Publication Number Publication Date
PL413705A1 true PL413705A1 (pl) 2017-03-13
PL227443B1 PL227443B1 (pl) 2017-12-29

Family

ID=57249834

Family Applications (1)

Application Number Title Priority Date Filing Date
PL413705A PL227443B1 (pl) 2015-08-27 2015-08-27 Nowe cykliczne peptydomimetyki, kompozycje je zawierające oraz ich zastosowanie do leczenia chorób związanych z angiogenezą

Country Status (4)

Country Link
US (1) US10800814B2 (pl)
EP (1) EP3341388B1 (pl)
PL (1) PL227443B1 (pl)
WO (1) WO2017033055A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023156531A (ja) * 2020-07-17 2023-10-25 参天製薬株式会社 Ｖｅｇｆ結合ペプチド

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL224854B1 (pl) * 2013-08-23 2017-02-28 Univ Warszawski Nowy peptydomimetyk o aktywności antyangiogennej i zawierająca go kompozycja farmaceutyczna

Also Published As

Publication number Publication date
EP3341388A1 (en) 2018-07-04
WO2017033055A1 (en) 2017-03-02
US10800814B2 (en) 2020-10-13
US20180327455A1 (en) 2018-11-15
PL227443B1 (pl) 2017-12-29
EP3341388B1 (en) 2019-12-18

Similar Documents

Publication Publication Date Title
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
MX2016012446A (es) Derivados de quinoxalina utiles como amortiguadaores de receptor del factor de crecimiento de fibroblastos (fgfr) cinasa.
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
MX386859B (es) Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos.
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
CL2015002932A1 (es) Inhibidores de proteína quinasa
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
MX393494B (es) Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
MX372914B (es) Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
MX383759B (es) Composiciones farmacéuticas de il-2.
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
EA201790461A1 (ru) Композиции внеклеточного матрикса
CL2015002897A1 (es) Inhibidores de bace1